Patents by Inventor Amy C. H. Lee

Amy C. H. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9187748
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: November 17, 2015
    Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
  • Publication number: 20150315584
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Application
    Filed: April 1, 2015
    Publication date: November 5, 2015
    Applicant: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: Marcia MacDonald, Amy C.H. Lee, lan MacLachlan
  • Patent number: 9035039
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 19, 2015
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Ammen P. Dhillon, Amy C. H. Lee, Ian MacLachlan
  • Patent number: 9023820
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: May 5, 2015
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
  • Publication number: 20150111945
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
    Type: Application
    Filed: March 28, 2014
    Publication date: April 23, 2015
    Inventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
  • Patent number: 8999950
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 7, 2015
    Assignee: Protiva Biotherapeutics Inc.
    Inventors: Ian MacLachlan, Amy C. H. Lee
  • Patent number: 8865675
    Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: October 21, 2014
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: James Heyes, Mark Wood, Alan Martin, Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
  • Publication number: 20140248338
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).
    Type: Application
    Filed: October 4, 2012
    Publication date: September 4, 2014
    Applicant: Protiva Biotherapeutics, Inc.
    Inventors: Ian MacLachlan, Amy C.H. Lee
  • Patent number: 8716464
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: May 6, 2014
    Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
  • Publication number: 20130123339
    Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Application
    Filed: May 12, 2011
    Publication date: May 16, 2013
    Applicant: PROTIVA BIOTHERAPEUTICS INC
    Inventors: James Heyes, Mark Wood, Alan Martin, Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
  • Patent number: 8236943
    Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: August 7, 2012
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
  • Publication number: 20120184595
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Application
    Filed: January 26, 2010
    Publication date: July 19, 2012
    Applicant: Protive Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C.H. Lee, Ian MacLachlan
  • Patent number: 8188263
    Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: May 29, 2012
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Ian MacLachlan, Adam Judge, Amy C. H. Lee, Vandana Sood
  • Publication number: 20110201667
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
    Type: Application
    Filed: July 20, 2010
    Publication date: August 18, 2011
    Applicants: Protiva Biotherapeutics, Inc., Trustees of Boston University, United States Army Medical Research and Materiel Command
    Inventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
  • Publication number: 20110195127
    Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Application
    Filed: June 30, 2010
    Publication date: August 11, 2011
    Applicant: Protiva Biotherapeutics, Inc.
    Inventors: Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
  • Publication number: 20110189300
    Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.
    Type: Application
    Filed: May 20, 2010
    Publication date: August 4, 2011
    Applicant: Protiva Biotherapeutics, Inc.
    Inventors: Ian MacLachlan, Lloyd B. Jeffs, Adam Judge, Amy C.H. Lee, Lorne R. Palmer, Vandana Sood
  • Publication number: 20090270481
    Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.
    Type: Application
    Filed: January 23, 2009
    Publication date: October 29, 2009
    Applicant: Protiva Biotherapeutics,Inc.
    Inventors: Ian MacLachlan, Adam Judge, Amy C.H. Lee, Vandana Sood